Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 7:20 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 3,539 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Saline placebo Clear all

Conditions: Heart Disease
Interventions: Dexmedetomidine, Placebo; Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years to 85 Years
Enrollment: 798 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2020
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: SARS-CoV Infection, Covid19
Interventions: SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period), Placebo (Initial Vaccination Period), SARS-CoV-2 rS/Matrix-M1 Adjuvant (Crossover Vaccination period), Placebo (Crossover Vaccination period), SARS-CoV-2 rS/Matrix-M1 Adjuvant (Booster Vaccination), SARS-CoV-2 rS/Matrix-M1 Adjuvant (Second Booster Vaccination); Biological · Other
Lead sponsor: Novavax; Industry
Eligibility: 12 Years and older
Enrollment: 33,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2023
U.S. locations: 144
States / cities: Birmingham, Alabama • Phoenix, Arizona • Tempe, Arizona + 110 more

Conditions: Amyotrophic Lateral Sclerosis (ALS)
Interventions: ORT247, Placebo; Drug
Lead sponsor: Orthogonal Neuroscience Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Upper Limb Spasticity
Interventions: DAXI for injection 250 U, DAXI for injection 375 U, DAXI for injection 500 U, Placebo; Biological · Other
Lead sponsor: Revance Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 26
States / cities: Downey, California • Fountain Valley, California • Long Beach, California + 22 more

Conditions: Pain
Interventions: Placebo, Liposomal bupivacaine; Drug
Lead sponsor: TriHealth Inc.; Other
Eligibility: 18 Years and older · Female only
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Clostridium Difficile Associated Disease
Interventions: Clostridium difficile vaccine, Placebo; Biological
Lead sponsor: Pfizer; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 185 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 12
States / cities: DeLand, Florida • Savannah, Georgia • Stockbridge, Georgia + 9 more

Conditions: HIV Infections
Interventions: DNA plasmid vaccine, Recombinant adenoviral serotype 5 (rAD5) vector vaccine, DNA vaccine placebo, HIV-1 recombinant adenovirus vaccine placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 2,504 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2017
U.S. locations: 22
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 15 more

Conditions: Obesity and Obesity-related Medical Conditions
Interventions: MET233 and MET097, Placebo, MET097; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 201 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Cypress, California

Conditions: Post-ERCP Acute Pancreatitis
Interventions: Indomethacin, Lactated Ringer's Solution, Normal Saline, Placebo; Drug
Lead sponsor: Cooper Norcross Health; Other
Eligibility: 18 Years and older
Enrollment: 192 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Camden, New Jersey

Conditions: Dengue Fever
Interventions: TAK-003, Placebo; Biological
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 923 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 14
States / cities: Huntsville, Alabama • Anaheim, California • Boise, Idaho + 11 more

Conditions: Ulcerative Colitis, FMT, Fecal Microbiota Transplant
Interventions: Metronidazole, Placebo, Vancomycin, Fecal Microbiota Transplantation; Drug · Biological
Lead sponsor: Ari M Grinspan; Other
Eligibility: 18 Years to 75 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Diabetes (DM)
Interventions: Glucagon, Saline (placebo); Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 45 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Sepsis
Interventions: Ketamine, Normal Saline placebo; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 21 Years to 100 Years
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Pain
Interventions: Botulinum Toxin A, Placebo - Saline; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: Stanford, California

Conditions: Anterior Cruciate Ligament Tear
Interventions: anakinra (150mg), Saline intraarticularly; Drug · Other
Lead sponsor: Cale Jacobs, PhD; Other
Eligibility: 14 Years to 40 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Influenza, COVID-19
Interventions: Influenza and COVID-19 Combination A, Licensed influenza vaccine, COVID-19 Vaccine, Influenza and COVID-19 Combination B, Placebo, Investigational influenza vaccine; Biological
Lead sponsor: BioNTech SE; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 8,795 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 106
States / cities: Athens, Alabama • Birmingham, Alabama • Mobile, Alabama + 76 more

Conditions: Elbow Fracture
Interventions: Glucocorticoids, Saline; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: End-Stage Renal Disease, End-Stage Kidney Disease, Kidney Failure, Chronic
Interventions: MK-2060, Placebo; Biological · Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 4
States / cities: Edgewater, Florida • Miami, Florida • Tampa, Florida + 1 more

Conditions: Hidradenitis Suppurativa
Interventions: Intralesional Triamcinolone 10 mg/mL, Intralesional Triamcinolone 20 mg/mL, Intralesional Triamcinolone 40 mg/mL, Placebo; Drug
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 13 Years and older
Enrollment: 11 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Obesity
Interventions: Ketamine, Ketamine plus magnesium, Placebo; Drug · Other
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 108 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Sickle Cell Disease, Vaso-occlusive Crisis
Interventions: Steroid arm, Placebo; Drug · Other
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 8 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Non-small Cell Lung Cancer (NSCLC)
Interventions: Paclitaxel, Carboplatin, CT-322, Bevacizumab, Bevacizumab placebo (ie saline solution); Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 255 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 20
States / cities: Tucson, Arizona • San Diego, California • Orlando, Florida + 17 more

Conditions: Mucopolysaccharidosis I, Mucopolysaccharidosis II, Mucopolysaccharidosis VI
Interventions: Adalimumab Injection [Humira], Saline Solution for Injection; Drug
Lead sponsor: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center; Other
Eligibility: 5 Years and older
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 1
States / cities: Torrance, California

Conditions: Zika Virus
Interventions: ZIKV-SJRP/2016-184 Strain, Experimental: ZIKV-Nicaragua/2016 Strain, Placebo; Biological
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 40 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Baltimore, Maryland

Search by objective public record fields.

Ancillary Effects of Dexmedetomidine Sedation After Cardiac Surgery

A Study to Evaluate the Efficacy, Immune Response, and Safety of a COVID-19 Vaccine in Adults ≥ 18 Years With a Pediatric Expansion in Adolescents (12 to<18 Years) at Risk for SARS-CoV-2

A First in Human Study of ORT247 in Healthy Volunteers

Efficacy and Safety of DaxibotulinumtoxinA for Injection for the Treatment of Adult Upper Limb Spasticity

Impact of Liposomal Bupivacaine Administered Following Placement of a Transobturator Suburethral Sling

A Study To Investigate A Clostridium Difficile Vaccine In Healthy Adults Aged 50 to 85 Years, Who Will Each Receive 3 Doses Of Vaccine.

Safety and Effectiveness of HIV-1 DNA Plasmid Vaccine and HIV-1 Recombinant Adenoviral Vector Vaccine in HIV-Uninfected, Circumcised Men and Male-to-Female (MTF) Transgender Persons Who Have Sex With Men

A Study of MET233 in Combination With MET097 in Individuals With Obesity or Overweight With or Without Diabetes

Lactated Ringers With or Without Rectal Indomethacin to Prevent Post-ERCP Pancreatitis

Lot-to-lot Consistency of 3 Lots of Tetravalent Dengue Vaccine (TDV) in Non-endemic Country(Ies) for Dengue

Refined Fecal Microbiota Transplantation (FMT) for Ulcerative Colitis (UC)

Studies of Insulin and Glucagon Action in the Liver

Immunomodulatory Properties of Ketamine in Sepsis

Subcutaneous Botulinum Toxin for Cutaneous Allodynia

IL-1RA Treatment in Patients With Acute ACL Tear and Painful Effusions

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Combined Modified RNA Vaccine Candidate Against COVID-19 and Influenza.

Steroid Administration for Articular Fractures of the Elbow (SAFE Trial)

A Study of MK-2060 in Participants With Chronic and/or End-Stage Kidney Disease (MK-2060-011)

Optimizing Intralesional Triamcinolone Dosing for Hidradenitis Suppurativa

Effect of Single Dose Ketamine and Magnesium on Postoperative Pain in Patients Undergoing Bariatric Surgery

Steroid Treatment for Sickle Cell Pain Crisis

Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer

Study to Evaluate the Safety and Efficacy of Adalimumab in MPS I, II, and VI

Evaluation of Two Zika Viruses for Use in Controlled Human Infection Models (CHIM)